Incidence figures were documented if the number of new cases of PRP in the population at risk studied over a given period of time was stated.
The great majority of published findings from infant at-risk studies have focused on isolated measures predicting later outcome.
Frequent endoscopic assessment also served to ensure that the at-risk study population was closely monitored for prompt detection of ulcer recurrence.
Since many of the infant at-risk studies are motivated by findings from adult populations and the theories emerging from these findings, we chose to organize our review accordingly.
However, nested case control studies and case-cohort studies were included in our meta-analysis because the at-risk study populations in each of the exposure categories are derived from cohort studies and diet exposure would have been investigated years before the onset of cancer, which would technically eliminate recall bias.
However, similar procedures combining all information from standard diagnostic measures and clinical observation and arriving at a 'clinical best estimate' ICD-10 diagnosis was used in the present study by an experience group to that used in other familial at-risk studies.
Similar procedures combining all information from standard diagnostic measures and clinical observation and arriving at a clinical best estimate ICD-10 diagnosis were used in the present study in line with other familial at-risk studies and were conducted by an experienced group of clinical researchers.
Subjects with at least one copy of these alleles have >1.95 times the relative risk of disease compared to the least at-risk genotype studied.
This study examined the prevalence of comorbidity and its impact on symptoms, functioning, cognition and transition to psychosis in the Longitudinal Youth at Risk Study (LYRIKS) sample.
The Longitudinal Youth at Risk Study (LYRIKS) commenced in Singapore in 2008, designed to comprehensively assess a group of ultra high risk (UHR) individuals and identify clinical, social, neuropsychological and biological risk factors unique to the local population.
The Prospective Study of Pravastatin in the Elderly at Risk study (PROSPER) followed 6000 individuals aged 70 to 82 for 3.2 years.
